The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease

Lars Holger Ehlers, Mark Lamotte, Sofia Monteiro, Susanne Sandgaard, Pia Holmgaard, Evan C. Frary, Niels Ejskjaer*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

1 Citation (Scopus)
19 Downloads (Pure)
Original languageEnglish
JournalDiabetes Therapy
Volume12
Issue number5
Pages (from-to)1523-1534
Number of pages12
ISSN1869-6953
DOIs
Publication statusPublished - May 2021

Bibliographical note

Publisher Copyright:
© 2021, The Author(s).

Keywords

  • Cardiovascular outcomes
  • Cost-effectiveness
  • Diabetes type 2
  • Empagliflozin
  • Liraglutide

Fingerprint

Dive into the research topics of 'The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease'. Together they form a unique fingerprint.

Cite this